Wells Fargo
IMDX

Wells Fargo’s Insight Molecular Diagnostics IMDX Stock Holding History

Wells Fargo’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3
Closed -$10 – 7289
2025
Q3 		$10 Hold
3
– – ﹤0.01% 6847
2025
Q2 		$9 Hold
3
– – ﹤0.01% 6926
2025
Q1 		$9 Buy
+3
New +$8 ﹤0.01% 6798
2024
Q2 		– Sell
-61
Closed -$179 – 7301
2024
Q1 		$179 Buy
61
+1
+2% +$3 ﹤0.01% 6515
2023
Q4 		$150 Buy
60
+2
+3% +$6 ﹤0.01% 6668
2023
Q3 		$181 Buy
58
+2
+4% +$7 ﹤0.01% 6613
2023
Q2 		$259 Buy
56
+16
+40% +$81 ﹤0.01% 6628
2023
Q1 		$284 Sell
40
-62
-61% -$460 ﹤0.01% 6678
2022
Q4 		$655 Buy
102
+63
+162% +$695 ﹤0.01% 6312
2022
Q3 		$1K Sell
39
-1
-3% -$17 ﹤0.01% 6415
2022
Q2 		$1K Sell
40
-1,406
-97% -$32K ﹤0.01% 6562
2022
Q1 		$43K Sell
1,446
-994
-41% -$31.8K ﹤0.01% 5727
2021
Q4 		$106K Sell
2,440
-1,315
-35% -$75.6K ﹤0.01% 5597
2021
Q3 		$268K Buy
3,755
+3,613
+2,544% +$332K ﹤0.01% 4982
2021
Q2 		$16K Sell
142
-1,087
-88% -$106K ﹤0.01% 5983
2021
Q1 		$128K Sell
1,229
-5,319
-81% -$505K ﹤0.01% 5372
2020
Q4 		$313K Buy
6,548
+4,511
+221% +$165K ﹤0.01% 4858
2020
Q3 		$56K Sell
2,037
-464
-19% -$13.3K ﹤0.01% 5468
2020
Q2 		$96K Sell
2,501
-2,525
-50% -$130K ﹤0.01% 5241
2020
Q1 		$247K Buy
5,026
+18
+0.4% +$882 ﹤0.01% 4547
2019
Q4 		$225K Buy
5,008
+523
+12% +$18.9K ﹤0.01% 4879
2019
Q3 		$189K Buy
4,485
+2,583
+136% +$102K ﹤0.01% 4993
2019
Q2 		$95K Buy
1,902
+1,900
+95,000% +$158K ﹤0.01% 5328
2019
Q1 		$0 Hold
2
– – ﹤0.01% 6328
2018
Q4 		$0 Sell
2
-3
-60% -$108 ﹤0.01% 6547
2018
Q3 		$0 Hold
5
– – ﹤0.01% 6513
2018
Q2 		$0 Sell
5
-30
-86% -$1.48K ﹤0.01% 6493
2018
Q1 		$1K Hold
35
– – ﹤0.01% 6274
2017
Q4 		$3K Buy
35
+17
+94% +$1.92K ﹤0.01% 6143
2017
Q3 		$2K Buy
18
+13
+260% +$1.36K ﹤0.01% 6159
2017
Q2 		$0 Hold
5
– – ﹤0.01% 6386
2017
Q1 		$0 Buy
5
+2
+67% +$231 ﹤0.01% 6436
2016
Q4 		$0 Hold
3
– – ﹤0.01% 6386
2016
Q3 		$0 Hold
3
– – ﹤0.01% 6297
2016
Q2 		$0 Sell
3
-71
-96% -$6.64K ﹤0.01% 6257
2016
Q1 		$7K Buy
+74
New +$6.55K ﹤0.01% 5803

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo's IMDX Position: Q4 2025 in Review

Wells Fargo sold out of Insight Molecular Diagnostics (IMDX) in Q4 2025, closing a stake of 3 shares — an estimated $10 sold.

Wells Fargo first reported a position in IMDX in Q1 2016 and held it in 36 quarters. The position peaked at $313K in Q4 2020. 35 funds tracked by Wall St. Rank hold IMDX as of Q4 2025.

  • Wells Fargo reported no remaining Insight Molecular Diagnostics position as of Q4 2025 after selling out during the quarter.
  • Wells Fargo sold 3 Insight Molecular Diagnostics shares in Q4 2025, an estimated $10.
  • Wells Fargo first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 36 quarters.
  • Wells Fargo's Insight Molecular Diagnostics position peaked at $313K in Q4 2020.
  • 35 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2025.

Based on Wells Fargo's 13F filing for Q4 2025, filed 13 Feb 2026.